文献速递心脑血管急症消化、代谢与肾脏急症

司美格鲁肽与心血管结局:基于SELECT试验基线及体脂测量变化的预设分析

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
PubMed 文献 · Lancet · 2025-10-22
一句话结论SELECT预设分析显示,司美格鲁肽降低MACE的获益在基线体重和腰围各分类中一致,且独立于体重下降,仅小部分由腰围减小介导。

SELECT试验纳入17 604例年龄≥45岁、BMI≥27 kg/m2、有心血管疾病但无糖尿病的患者,随机接受每周一次司美格鲁肽2.4 mg或安慰剂。预设分析显示,司美格鲁肽组中基线体重和腰围较低与MACE发生率较低相关(体重每低5 kg HR 0.96,腰围每小5 cm HR 0.96)。安慰剂组中基线腰围较低与MACE风险较低相关,但体重下降反而与MACE风险增加相关。司美格鲁肽的心血管保护作用独立于基线肥胖程度和体重下降,仅约33%的获益通过腰围减小介导。

要点

  • 司美格鲁肽2.4 mg每周一次在基线体重和腰围各分类中均一致降低MACE,获益不依赖于基线肥胖程度。
  • 司美格鲁肽组基线体重每低5 kg,MACE风险平均降低4%(HR 0.96,95%CI 0.94-0.99,p=0.001)。
  • 司美格鲁肽组基线腰围每小5 cm,MACE风险平均降低4%(HR 0.96,95%CI 0.93-0.99,p=0.004)。
  • 接受司美格鲁肽者第20周体重下降与后续MACE风险无线性趋势,但第20周腰围减少越多后续MACE风险越低。
  • 约33%的MACE获益通过腰围减小介导(校正时变腰围变化后HR 0.86,95%CI 0.77-0.97),提示部分获益机制超越体脂减少。

适用人群与场景

  • 年龄至少45岁、BMI至少27 kg/m2、有心血管疾病但无糖尿病的患者,来自41个国家804个中心。

研究设计与关键结果

  • SELECT为随机对照试验,纳入17 604例患者,1:1随机接受每周一次司美格鲁肽2.4 mg或安慰剂,主要终点为首发MACE(心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点)。
  • 司美格鲁肽组基线体重每低5 kg,MACE风险平均降低4%(HR 0.96,95%CI 0.94-0.99,p=0.001);基线腰围每小5 cm,MACE风险平均降低4%(HR 0.96,95%CI 0.93-0.99,p=0.004)。
  • 安慰剂组基线腰围每小5 cm与MACE风险较低相关(HR 0.96,95%CI 0.94-0.99,p=0.007),但基线体重与MACE风险无关(HR 0.99,95%CI 0.97-1.01,p=0.28),且体重下降反而与MACE风险增加相关。
  • 司美格鲁肽组第20周体重下降与后续MACE风险无线性趋势,但第20周腰围减少越多后续MACE风险越低;第104周腰围减少与试验期间MACE风险降低相关。
  • 约33%的MACE获益通过腰围减小介导(校正时变腰围变化后HR 0.86,95%CI 0.77-0.97)。

证据类型、等级与局限

  • 证据类型:随机对照试验SELECT的预设分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 司美格鲁肽2.4 mg每周一次的心血管保护作用在基线体重和腰围各分类中一致,处方决策可不依赖基线肥胖程度。
  • 司美格鲁肽的MACE获益独立于体重下降,仅小部分与腰围减小相关,提示部分获益机制超越体脂减少;作者认为这提示超越减重的机制参与获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes. We report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk.

METHODS: Patients aged at least 45 years, with a BMI of at least 27 kg/m2 were enrolled in 41 countries (804 sites) and randomised 1:1 to once-weekly semaglutide 2·4 mg or placebo. The primary outcome was time to first MACE (composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). Adiposity measures included weight and waist circumference. In this analysis, risk of MACE occurring after 20 weeks was assessed between patients by adiposity changes in the first 20 weeks and, in a separate analysis, all in-trial MACE were assessed between patients by adiposity changes over 104 weeks. This trial is registered with ClinicalTrials.gov, NCT03574597.

FINDINGS: Semaglutide significantly reduced MACE incidence compared with placebo among 17 604 patients enrolled in SELECT, with consistent benefits across all baseline weight and waist circumference categories. In the semaglutide group, analyses for linear trends showed lower baseline bodyweight and waist circumference were associated with lower incidence of MACE-an average 4% reduction in risk per 5 kg lower bodyweight (hazard ratio [HR] 0·96 [95% CI 0·94-0·99]; p=0·001) and per 5 cm smaller waist circumference (0·96 [0·93-0·99]; p=0·004). In the placebo group, lower baseline waist circumference (0·96 [0·94-0·99]; p=0·007), but not bodyweight (0·99 [0·97-1·01]; p=0·28), was associated with a lower MACE risk and weight loss was paradoxically associated with increased MACE risk. In those receiving semaglutide there was no linear trend linking weight loss at week 20 to subsequent MACE risk, but greater waist circumference reduction at week 20 was associated with lower subsequent MACE risk, and waist circumference reduction by week 104 was associated with lower in-trial risk of MACE. An estimated 33% of the observed benefit on MACE was mediated through waist circumference reduction (HR 0·86 [95% CI 0·77-0·97] after adjustment for time-varying changes in waist circumference).

INTERPRETATION: The cardioprotective effects of semaglutide were independent of baseline adiposity and weight loss and had only a small association with waist circumference, suggesting some mechanisms for benefit beyond adiposity reduction.

FUNDING: Novo Nordisk.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025. PMID: 41138739. doi:10.1016/S0140-6736(25)01375-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。